Novo Nordisk signs $1.3 billion deal with Nanexa for long-acting drug technology

Novo Nordisk Nanexa PharmaShell drug delivery technology obesity medication

Novo Nordisk has entered into a global exclusive licensing and collaboration agreement with Swedish biotech company Nanexa. The deal, which could reach a total value of approximately $1.33 billion (€1.165 billion), focuses on Nanexa’s PharmaShell drug-delivery technology.

PharmaShell utilizes atomic layer deposition (ALD) to apply an ultra-thin inorganic coating to individual drug particles. This technology is designed to regulate the release of active ingredients, enabling the development of long-acting injectable formulations. The collaboration aims to extend the dosing intervals for peptide-based medicines used in treating obesity, type 2 diabetes, and other cardiometabolic diseases, potentially moving from weekly injections to monthly or even quarterly administration.

The financial structure includes up to €615 million in upfront, development, and regulatory milestone payments, with additional payments tied to sales milestones and low single-digit royalties on future global net sales. Novo Nordisk will lead the global development and commercialization of the resulting products. Following the announcement, Nanexa’s shares surged by over 100% on the Stockholm exchange.

Entities

Connected Intelligence · Eli Lilly · Huber+Suhner · Motion Applied · Nanexa · Novo Nordisk · PharmaShell · Stockholm · Stockholm Stock Exchange

Claims

What the coverage asserts, and how many sources carry each claim.

[● 2 SOURCES] The acquisition aims to expand Huber+Suhner's offerings for railway communication.
[○ 1 SOURCE] The deal includes approximately 45 software specialists from Connected Intelligence.
[● 2 SOURCES] Huber+Suhner has signed an agreement to acquire the Connected Intelligence business from Motion Applied Limited.
[● 2 SOURCES] The acquisition will allow Huber+Suhner to offer integrated end-to-end connectivity systems.
[● 7 SOURCES] The total value of the agreement could reach approximately $1.3 billion. www.saludiario.com · www.ibtimes.com · mugglehead.com · www.merca2.es · radioh.no · +2 more
[● 6 SOURCES] The agreement includes up to €615 million in upfront and milestone payments. www.ibtimes.com · mugglehead.com · www.merca2.es · radioh.no · www.sharedeals.de · +1 more
[● 5 SOURCES] Nanexa shares rose more than 100% following the announcement. www.privataaffarer.se · www.ibtimes.com · mugglehead.com · www.merca2.es · www.finanzen.net
[● 7 SOURCES] The agreement covers up to five development programs. www.saludiario.com · www.ibtimes.com · mugglehead.com · www.merca2.es · radioh.no · +2 more
[● 7 SOURCES] The deal aims to develop long-acting formulations for monthly or quarterly administration. www.saludiario.com · www.ibtimes.com · mugglehead.com · www.merca2.es · radioh.no · +2 more
[● 7 SOURCES] Novo Nordisk signed a global exclusive licensing agreement with Nanexa. www.saludiario.com · www.ibtimes.com · mugglehead.com · www.merca2.es · radioh.no · +2 more
[● 7 SOURCES] The technology targets obesity, type 2 diabetes, and cardiometabolic diseases. www.saludiario.com · www.ibtimes.com · mugglehead.com · www.merca2.es · radioh.no · +2 more
[● 7 SOURCES] Nanexa developed the PharmaShell technology. www.saludiario.com · www.ibtimes.com · mugglehead.com · www.merca2.es · radioh.no · +2 more